PT-112 for Thymoma and Thymic Carcinoma
This study is testing a drug called PT-112 for people with thymoma or thymic carcinoma (cancers of the thymus gland) that has come back or gotten worse after previous treatment. There are currently no approved drugs for these conditions once they recur, so new options are needed. PT-112 works by killing cancer cells and helping your body's immune system fight the cancer. Researchers want to see if PT-112 can shrink tumors. You may be able to join if you are 18 or older and have received at least one platinum-based chemotherapy, or if you have refused standard chemotherapy. The study plans to enroll 53 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 53 participants.
- What's involved
- PT-112 will be given through a vein (intravenously) on specific days in 28-day cycles. Tumor shrinkage will be checked every 8 weeks while on treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Tumor shrinkage will be assessed every 8 weeks while on treatment, and then every 3 months after that for up to 8 years from the start of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05104736
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Recruiting
PHASE2Ages 18+InterventionalTreatmentNational Cancer Institute (NCI)Government-funded
~53 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:PT-112
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
overall response rate (ORR)
Measured over assessed every 8 weeks while on treatment and then every 3 months after that for a maximum of 8 years from the start of study
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Arun Rajan, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants must have histologically confirmed thymoma or thymic carcinoma.
Participants should have received at least one prior line of platinum-based chemotherapy. For participants who have refused cytotoxic chemotherapy, a rationale for refusal to receive standard first-line therapy will be captured in the case report form and the medical record. Progressive disease must be documented prior to study entry and participants must have advanced, unresectable disease that is not amenable to surgical resection.
Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.
Participants must be aged \>=18 years.
ECOG performance status \<=1.
Participants must have adequate organ and marrow function as defined below:
absolute neutrophil count \>= 1,500/mm3 OR \>= 1.5 x 10(9)/L
platelets \>=100,000/mm3 OR (Bullet) 100 x 10(9)/L
hemoglobin \>= 9g/dL (may have been transfused, at least 7 days prior)
total bilirubin \<= 1.5 x the upper limit of normal range (ULN)
AST(SGOT)/ALT(SGPT) \<= 2.5 x ULN OR \<= 5 x ULN for participants with documented metastatic disease to the liver
creatinine \<= 1.5x ULN OR:
creatinine clearance \>= 60 mL/min/1.73 m2 calculated by calculated using eGRF in the clinical lab
Negative serum or urine pregnancy test at screening for individuals of childbearing potential (IOCBP). NOTE: IOCBP is defined as any individual who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal. Absence of pregnancy must be demonstrated unless there is proven menopause (age \>= 50 years and last menarche \>= 3 years, or documented menopausal sex hormone profile, or surgical castration) at screening.
Participants must not become pregnant or start breast feeding during the study. Breastfeeding should be discontinued if the mother is treated with PT-112.
Individuals of child-bearing potential and those that can father children with a sexual partner of childbearing potential must use medically effective contraception during the study and for 6 months after the last dose of study medication.
Participants with previously treated brain or CNS metastases are eligible provided that the participant has recovered from any acute side effects of radiotherapy and does not require treatment with steroids, and any whole brain radiation therapy was completed at least 2 weeks prior to initiation of study therapy.
Ability of participant to understand and the willingness to sign a written informed consent document.
Exclusion
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PT-112. Since there is no definitive list of compounds of similar chemical or biologic composition to PT-112, the principal investigator if in doubt, will report known allergies to the pharmacist to make a determination as to whether it is safe to enroll a participant.
Concurrent treatment with a non-permitted drug.
Concurrent anticancer treatment within 14 days before initiation of study therapy (includes radiotherapy; however, palliative bone-directed radiotherapy is permitted).
Major surgery within 14 days before enrollment (excluding prior diagnostic biopsy).
Concurrent systemic therapy with immunosuppressive agents within 14 days (or 5 half-lives of a drug, whichever is shorter) before initiation of study therapy.
Use of hormonal agents for anti-cancer therapy within 14 days before initiation of study therapy; or use of any investigational drug within 14 days before initiation of study therapy.
History of previous malignant disease within the last 2 years with the following exceptions: basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary or follicular thyroid carcinoma, and non-muscle invasive bladder cancer.
Active infection requiring systemic therapy or significant acute or chronic infections including, among others:
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
Known history of testing positive for HIV or known acquired immunodeficiency syndrome with a detectable viral load. However, participants with HIV who have an undetectable viral load and are on stable doses of Highly Active Antiretroviral Therapy (HAART) can be screened for the study.
Persisting toxicity related to prior therapy (NCI CTCAE v. 5 Grade \> 1) with the exception of, alopecia, sensory neuropathy Grade \<= 2 and hearing loss Grade \<=2.
Known alcohol or drug abuse.
Uncontrolled intercurrent illness including, but not limited to the following:
Cardiovascular: SYMPTOMATIC congestive heart failure, unstable angina pectoris or cardiac arrhythmia, either active or within the past 6 months
Respiratory: Pneumonitis or Idiopathic pulmonary fibrosis (not radiation-associated fibrosis), either active or within the past 6 months
Gastrointestinal: Immune colitis or inflammatory bowel disease, either active or within the past 6 months
Hematological: Bleeding diathesis or major bleeding events, either active or within the past 6 months
Other: psychiatric illness/social situations that would limit compliance with study requirements, including active suicidal ideation or behavior, either active or within the past 12 months
Administration of live vaccines within 4 weeks prior to treatment. COVID-19 vaccines are permitted at screening.
What this trial measures
- overall response rate (ORR)assessed every 8 weeks while on treatment and then every 3 months after that for a maximum of 8 years from the start of study
best overall response is the best response recorded per RECIST 1.1 criteria, from the start of the treatment until disease progression/recurrence